Kaposi sarcoma among people living with HIV in the French DAT’AIDS cohort between 2010 and 2015

Although antiretroviral therapy (ART) has reduced the risk of Kaposi sarcoma (KS), KS cases still occur in HIV‐infected people.

C. Charpentier | C. Katlama | Y. Yazdanpanah | P. Muret | E. Delaporte | C. Delpierre | L. Cuzin | M. Alvarez | B. Hoen | O. Baud | F. Raffi | F. Lucht | P. Colson | C. Pradier | S. Fafi-Kremer | F. Lescure | C. Dhiver | S. Brégigeon | G. Peytavin | C. Tamalet | D. Descamps | V. Ferré | P. Perre | G. Martin-Blondel | P. Delobel | B. Pilmis | C. Clavel | P. Consigny | L. Cotte | Y. N'Guyen | F. Biron | A. Boibieux | L. Meddeb | H. Tissot Dupont | D. Boutoille | E. Paredes | M. Valantin | C. Chidiac | M. Pradier | N. Lerolle | P. Tattevin | S. Pillet | E. Botelho-Nevers | A. Frésard | A. Gagneux-Brunon | I. Poizot-Martin | K. Sauné | A. Chéret | L. Hocqueloux | C. Blanc | C. Arvieux | A. Barrail-Tran | A. Gervais | B. Bonnet | V. Le Moing | S. Le Gac | R. Palich | R. Agher | S. Seang | L. Schneider | C. Rabaud | E. Tuaillon | S. Matheron | F. Valour | T. Prazuck | B. Tressières | R. Landman | C. Charlier | F. Lanternier | M. Vidal | O. Lesens | P. Dellamonica | P. Bossi | A. Cabié | P. Choisy | C. Boulard | C. Chirouze | T. Ferry | M. Partisani | P. Loubet | O. Robineau | D. Rey | C. Lions | I. Ravaux | I. Lamaury | M. Piffaut | A. Sève | M. Valette | A. Motte | Q. Lepiller | R. Garraffo | N. Viget | C. Jacomet | C. Rioux | V. Reliquet | S. Lariven | F. Bénézit | M. Baldeyrou | K. Bouiller | F. Ader | S. Abel | S. Casanova | C. Brochier | T. Perpoint | A. Makinson | B. Montes | J. Turmel | P. Puglièse | J. Durant | V. Mondain | C. Ceppi | I. Perbost | E. Cua | J. Ghosn | A. Boucher | É. Demonchy | K. Risso | V. Brodard | A. Ménard | O. Grossi | A. Meybeck | L. Bocket | I. Alcaraz | C. Allavena | C. Drobacheff-Thiebaut | O. Lortholary | C. Aumeran | M. Revest | L. Lelièvre | D. Merrien | M. Cavellec | A. Rodallec | H. Laurichesse | C. Duvivier | O. Aubry | A. Raoux | E. Billaud | E. Curlier | J. Chapplain | M. Hentzien | F. Souala | M. Dupont | P. Miailhes | M. Batard | A. De Monte | A. Debard | Z. Julia | M. Lefebvre | F. Danion | S. Roux | C. Triffault-Fillit | A. Maillard | S. Patrat-Delon | M. Poinot | C. Pronier | C. Biron | C. Deschanvres | N. Atoui | E. Ressiot | E. Andre-Garnier | K. Jidar | F. Bani-Sadr | C. Herrmann-Storck | T. Guimard | I. Fabre | S. Secher | S. Leautez | E. Teicher | L. Porte | P. Parize | V. Baclet | V. Obry-Roguet | O. Zaegel-Faucher | H. Laroche | S. Galie | M. Orticoni | M. Soavi | R. Guery | N. Mrozek | C. Tomei | M. Illiaquer | I. Touitou | V. Joly | D. Chirio | L. Boyer | C. Bernaud | Y. Quertainmont | M. Morrier | T. Jovelin | N. Hall | F. Louni | A. Naqvi | L. Hustache-Mathieu | A. Brunel | K. Amazzough | C. Cheneau | M. Priester | C. Bernard-Henry | C. Merle De Boever | L. Osei | V. Rio | J. Lourenço | F. Touam | C. Louisin | D. Lambert | J. Berger | I. Kmiec | A. Soria | I. Jaquet | F. Ajana | M. Bistoquet | A. Ivanova | T. Huleux | S. Pierre-François | C. Brunet-cartier | S. Bouchez | C. Goujard | G. Cessot | F. Boulard | B. Henry | O. Cabras | R. Ouissa | J. Pasquier | C. Gubavu | A. Duréault | S. Ferrando | P. Morineau | M. André | T. Bonijoly | P. Roger | C. Michelangeli | E. Rosenthal | M. Receveur | P. Fischer | C. Debreux | J. Sinteff | J. Prouteau | F. Lemaitre | A. Brunet | F. Bozon | P. Letertre-Gibert | N. Oran | J. Goesch | K. Guitteaud | A. Galinier | S. Breaud | N. Biezunski | A. Foltzer | M. Delestan | T. May | R. Tubiana | P. Martinet | G. Benabdelmoumen | E. Mautort | C. Etienne | M. Ducassou | V. Corbin | E. Aïssi | B. Lafon-Desmurs | N. Meftah | V. Ronat | O. Babre | O. Bollangier | L. Laine | S. Degroodt | A. Belkhir | A. Madrid | M. Martin‐Degioanni | M. Mokhtari | A. Ritleng | K. Rome | C. Varache | A. Montoya Ferrer | M. Bouillon | A. Mąka | B. Prouvost-Keller | S. Wehrlen-Pugliese | G. Zouzou | O. Deradji | P. Lansalot | P. Geneau de Lamarliere | C. Mackoumbou-Nkouka | M. Landon | E. Sidani | S. Sausse | C. Guennoun | M. Poisson-Vanier | C. Daniel | A. Becker | J. Reynes | G. Thomas | C. Drobacheff‐Thiébaut | S. Léautez | S. Wehrlen‐Pugliese

[1]  C. Katlama,et al.  Recurrence and Occurrence of Kaposi's Sarcoma in Patients Living With Human Immunodeficiency Virus (HIV) and on Antiretroviral Therapy, Despite Suppressed HIV Viremia. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  N. Ko,et al.  The moderator effect of retention in care on late presentation in HIV-infected patients , 2020, AIDS care.

[3]  I. Zalaudek,et al.  Diagnosis and treatment of Kaposi's sarcoma: European consensus-based interdisciplinary guideline (EDF/EADO/EORTC). , 2019, European journal of cancer.

[4]  C. Charpentier,et al.  Missed opportunities of HIV pre-exposure prophylaxis in France: a retrospective analysis in the French DAT’AIDS cohort , 2019, BMC Infectious Diseases.

[5]  A. Burchell,et al.  Late diagnosis, delayed presentation and late presentation among persons enrolled in a clinical HIV cohort in Ontario, Canada (1999–2013) , 2018, HIV medicine.

[6]  V. Supervie,et al.  HIV testing within general practices in Europe: a mixed-methods systematic review , 2018, BMC Public Health.

[7]  G. Esson,et al.  HIV testing in dermatology – a national audit , 2018, International journal of STD & AIDS.

[8]  P. Kazembe,et al.  Pediatric Kaposi sarcoma in context of the HIV epidemic in sub-Saharan Africa: current perspectives , 2018, Pediatric health, medicine and therapeutics.

[9]  R. Yarchoan,et al.  HIV‐Associated Cancers and Related Diseases , 2018, The New England journal of medicine.

[10]  Yue Chen,et al.  Global epidemiology of human herpesvirus 8 in men who have sex with men: A systematic review and meta‐analysis , 2018, Journal of medical virology.

[11]  R. Diaz,et al.  Late Presentation HIV/AIDS Is Still a Challenge in Brazil and Worldwide. , 2017, AIDS research and human retroviruses.

[12]  S. Esser,et al.  Profil der Kaposi-Sarkom-Patienten im Kompetenznetz HIV/AIDS , 2018, Der Hautarzt.

[13]  S. Rebaudet,et al.  HHV8 and Kaposi's sarcoma: should we really give up protease inhibitors in all HIV-infected patients? , 2017, AIDS.

[14]  J. Enkelmann,et al.  Late HIV presentation – missed opportunities and factors associated with a changing pattern over time , 2017, International journal of STD & AIDS.

[15]  A. Friedman-kien,et al.  An Update on Kaposi’s Sarcoma: Epidemiology, Pathogenesis and Treatment , 2016, Dermatology and Therapy.

[16]  Richard D Moore,et al.  Changes in Clinical Context for Kaposi's Sarcoma and Non-Hodgkin Lymphoma Among People With HIV Infection in the United States. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  O. Kirk,et al.  Late presentation to HIV care despite good access to health services: current epidemiological trends and how to do better. , 2016, Swiss medical weekly.

[18]  D. Cattaneo,et al.  Relapse of Kaposi's Sarcoma and HHV-8 viremia in an HIV-infected patient switching from protease inhibitor to integrase inhibitor-based antiretroviral therapy. , 2016, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[19]  E. Netchiporouk,et al.  Iatrogenic Kaposi's sarcoma after immunosuppressive treatment for granulomatosis with polyangiitis (Wegener's) , 2015, JAAD case reports.

[20]  J. Kramer,et al.  Use of boosted protease inhibitors reduces Kaposi sarcoma incidence among male veterans with HIV infection. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  S. Brégigeon,et al.  Kaposi's sarcoma in a treated and well-controlled HIV infected patient: Discussion on the role of immunosenescence , 2014 .

[22]  Shou-Jiang Gao,et al.  HIV-1 Tat Promotes Kaposi’s Sarcoma-Associated Herpesvirus (KSHV) vIL-6-Induced Angiogenesis and Tumorigenesis by Regulating PI3K/PTEN/AKT/GSK-3β Signaling Pathway , 2013, PloS one.

[23]  M. Guiguet,et al.  Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. , 2009, The Lancet. Oncology.

[24]  X. Fang,et al.  Human immunodeficiency virus type 1 Tat accelerates Kaposi sarcoma-associated herpesvirus Kaposin A-mediated tumorigenesis of transformed fibroblasts in vitro as well as in nude and immunocompetent mice. , 2009, Neoplasia.

[25]  L. Cuzin,et al.  A large French prospective cohort of HIV‐infected patients: the Nadis Cohort , 2009, HIV medicine.

[26]  N. Neil,et al.  A Retrospective Analysis of AIDS-Associated Kaposi’s Sarcoma in Patients With Undetectable HIV Viral Loads and CD4 Counts Greater Than 300 cells/mm3 , 2009, Journal of the International Association of Physicians in AIDS Care.

[27]  D. Dittmer,et al.  More on HIV-associated Kaposi's sarcoma. , 2008, The New England journal of medicine.

[28]  É. Oksenhendler,et al.  Low T cell responses to human herpesvirus 8 in patients with AIDS-related and classic Kaposi sarcoma. , 2006, The Journal of infectious diseases.

[29]  P. Moore,et al.  Detection of herpesvirus-like DNA sequences in Kaposi's sarcoma in patients with and those without HIV infection. , 1995, The New England journal of medicine.